Table 2. Univariate and multivariate analysis of OS in gastric cancer patients with multi-organ metastases.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | |||||
| <70 years | Reference | Reference | |||
| ≥70 years | 1.25 (1.09–1.44) | 0.002* | 1.29 (1.11–1.49) | <0.001* | |
| Sex | |||||
| Female | Reference | – | – | ||
| Male | 1.00 (0.87–1.16) | 0.972 | – | – | |
| Race | |||||
| Black | Reference | Reference | |||
| White | 0.82 (0.67–0.99) | 0.038* | 0.79 (0.65–0.96) | 0.018* | |
| Other | 0.85 (0.65–1.09) | 0.203 | 0.82 (0.63–1.07) | 0.146 | |
| Primary site | |||||
| Cardia | Reference | – | – | ||
| Fundus | 1.10 (0.83–1.46) | 0.519 | – | – | |
| Body | 1.06 (0.81–1.40) | 0.671 | – | – | |
| Antrum | 1.14 (0.89–1.46) | 0.304 | – | – | |
| Pylorus | 0.86 (0.45–1.67) | 0.661 | – | – | |
| Lesser | 0.86 (0.62–1.19) | 0.353 | – | – | |
| Greater | 1.29 (0.88–1.90) | 0.187 | – | – | |
| Overlapping | 1.20 (0.92–1.57) | 0.170 | – | – | |
| Stomach, NOS | 1.03 (0.84–1.28) | 0.755 | – | – | |
| Histological type | |||||
| Adenocarcinoma | Reference | – | – | ||
| Mucinous adenocarcinoma | 1.32 (0.71–2.47) | 0.380 | – | – | |
| Signet ring cell carcinoma | 1.19 (0.96–1.48) | 0.112 | – | – | |
| Other | 1.12 (0.90–1.38) | 0.316 | – | – | |
| Regional nodes examined | |||||
| ≤15 | Reference | – | – | ||
| >15 | 0.81 (0.26–2.53) | 0.723 | – | – | |
| Unknown | 1.36 (0.97–1.92) | 0.077 | – | – | |
| Metastases | |||||
| Liver + Lung | Reference | Reference | |||
| Liver + Bone | 0.89 (0.75–1.05) | 0.162 | 0.85 (0.71–1.00) | 0.054 | |
| Liver + Brain | 1.17 (0.73–1.87) | 0.525 | 1.25 (0.78–2.02) | 0.357 | |
| Lung + Bone | 1.09 (0.87–1.38) | 0.447 | 0.98 (0.77–1.24) | 0.844 | |
| Lung + Brain | 0.75 (0.38–1.44) | 0.383 | 0.74 (0.38–1.44) | 0.374 | |
| Bone + Brain | 1.38 (0.78–2.46) | 0.271 | 1.22 (0.68–2.18) | 0.503 | |
| Liver + Lung + Bone | 0.94 (0.75–1.18) | 0.603 | 0.93 (0.74–1.17) | 0.540 | |
| Liver + Lung + Brain | 1.26 (0.78–2.01) | 0.345 | 1.58 (0.98–2.55) | 0.062 | |
| Liver + Bone + Brain | 1.37 (0.75–2.51) | 0.303 | 1.96 (1.05–3.67) | 0.036* | |
| Lung + Bone + Brain | 0.25 (0.09–0.67) | 0.006* | 0.41 (0.15–1.12) | 0.081 | |
| Liver + Lung + Bone + Brain | 1.47 (0.76–2.85) | 0.252 | 1.35 (0.69–2.62) | 0.379 | |
| Tumor size | |||||
| <90 mm | Reference | Reference | |||
| ≥90 mm | 1.40 (1.05–1.88) | 0.023* | 1.35 (1.01–1.82) | 0.045* | |
| Unknown | 1.14 (0.99–1.32) | 0.061 | 1.08 (0.94–1.25) | 0.275 | |
| Grade | |||||
| Grade I | Reference | Reference | |||
| Grade II | 1.44 (0.93–2.23) | 0.103 | 1.25 (0.80–1.94) | 0.324 | |
| Grade III, Grade IV | 2.09 (1.37–3.21) | 0.001* | 1.99 (1.30–3.06) | 0.002* | |
| Stage T | |||||
| T0-1 | Reference | – | – | ||
| T2 | 0.98 (0.64–1.51) | 0.937 | – | – | |
| T3 | 0.92 (0.71–1.18) | 0.495 | – | – | |
| T4 | 1.05 (0.84–1.31) | 0.658 | – | – | |
| TX | 1.05 (0.88–1.26) | 0.561 | – | – | |
| Stage N | |||||
| N0 | Reference | – | – | ||
| N1 | 0.98 (0.84–1.15) | 0.818 | – | – | |
| N2 | 0.94 (0.69–1.27) | 0.670 | – | – | |
| N3 | 1.23 (0.90–1.69) | 0.195 | – | – | |
| NX | 1.13 (0.92–1.39) | 0.242 | – | – | |
| Surg prim site | |||||
| No | Reference | – | – | ||
| Yes | 0.78 (0.53–1.17) | 0.232 | – | – | |
| Surg dis site | |||||
| No | Reference | Reference | |||
| Yes | 0.51 (0.33–0.78) | 0.002* | 0.52 (0.33–0.82) | 0.005* | |
*, P<0.05. OS, overall survival; HR, hazard ratio; CI, confidence interval.